On April 25, the medical sector suddenly went up in intraday trading, with Puri ophthalmology and Kai Healthcare rising by more than 4%, leading the rise of 50 constituent stocks of CSH Medical! Many stocks, such as Tongshi Medical, Le Pu Medical, and El Ophthalmology, rose more than 3%.

ETF, medical sector representative medical ETF (512170) shock pull up, as of press release floor price up 1Crabtraps.25%! It is worth mentioningCrabtrapsIs, the previous 3 trading days, medical ETF (512170) continuously received the positive line.

In terms of funds, the recent absorption of the ETF is significant. Data show that as of April 24, the medical ETF (512170) has a cumulative net inflow of nearly 1 billion yuan in the past month.

According to the latest news from the industry, Li Li, secretary of the party leading group and director of the State Drug Administration, inspected and investigated relevant pharmaceutical enterprises in Shanghai from April 23 to 24, and presided over a forum to listen to opinions and suggestions on the development of the biomedical industry.

Li Li stressed that pharmaceutical enterprises and drug regulatory departments should jointly do a good job in ensuring safety and promoting development. Pharmaceutical enterprises should firmly establish the concept that quality is life, fully implement the main responsibility, strengthen the investigation and rectification of hidden risks, increase investment in scientific research, introduce and train talents, and create a good environment for scientific research and innovation. we will concentrate our efforts on tackling key problems in biomedical frontier basic research and core technologies, and constantly improve our innovation ability. Drug regulatory departments should adhere to the combination of supervision and service, continue to deepen the reform of the review and approval system, actively support pharmaceutical R & D and innovation, and promote China from a big pharmaceutical country to a pharmaceutical power.

Guoxin Securities latest research report said that the pharmaceutical industry is currently in low growth, low profitability, undervalued, low trading attention, or is entering a major layout range of medium-and long-term upward inflection point. It is suggested to focus on the following directions: 1) innovative drugs and innovative medical device enterprises; 2) companies with international ability and potential; 3) meet the "four new" (new track, new technology, new platform, new mechanism) standards, industries and companies that represent new productivity; 4) products and industries that can meet the needs of C home care for the aged and at their own expense under the background of silver economy.

Public data show that the CSI component stocks tracked by Medical ETF (512170) comprehensively cover the leaders in the field of medical devices and medical services, of which the weight of medical devices is about 40%, directly benefiting from the new medical infrastructure in the post-epidemic era; medical services + medical beauty weight is about 50%, covering 10 CXO concept stocks, directly benefiting from the general trend of the era, such as the aging population, the upgrading of medical consumption and medical beauty.

The picture is from iFinD, Shanghai and Shenzhen Stock Exchange and Warburg Fund, as of April 25. Risk hint: medical ETF (512170) and its linked funds passively track the CSI Medical Index. The index base date is 2004.12.31, released on October 31, 2014. The composition of the index stocks is timely adjusted according to the index compilation rules. In this paper, the index stocks are only displayed, and the individual stocks are not described as any form of investment advice, nor do they represent the position information and trading trends of any fund under the manager. The risk grades of the fund and its linked funds assessed by the fund manager are R3-medium risk and R4-medium-high risk respectively, which are suitable for balanced (C3), active (C4) and above investors, respectively. Any information that appears in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, any form of expression, etc.) is for reference only and the investor is responsible for any discretionary investment behavior. In addition, any point of view, analysis and forecast in this article does not constitute any form of investment advice to the reader, nor is it liable for direct or indirect losses arising from the use of the contents of this article. Fund investment is risky, the past performance of the fund does not represent its future performance, and the performance of other funds managed by fund managers does not constitute a guarantee of fund performance, so fund investment should be cautious.